An AMC researcher primarily using mass spec for the development, manufacturing and quality control of biologic therapeutics, target validation, and metabolomics. This stakeholder remarks that, of current so-called next-generation proteomics platforms, few are truly doing anything new or unique; in their opinion, the term next-generation should be reserved for technologies such as that promised by Quantum-Si, i.e., the ability to sequence unknown proteins de novo, with high amino acid sequence resolution. Nautilus, Encodia, and Seer are other players, though none are yet validated. While the goal of true protein sequencing is impeded by numerous biophysical challenges, a true next-generation proteomic platform adds far more value than existing, antibody recognition-based approaches. Of the existing antibody-based platforms,Standard BioTools / Fluidigm was seen as attractive. The most important criteria for proteomics offerings are, in this stakeholder’s view, specificity, instrument price, and price per assay.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.